Phase 2 of the clinical study for the drug eluxadoline showed improvements for patients with irritable bowel syndrome with diarrhea over the placebo treatment, according to a Healio report.
The trial involved 807 adult patients with IBS who were randomly assigned to either various doses of eluxadoline or an oral placebo. Researchers tracked the clinical response to the treatments for 14 weeks with week four being the primary endpoint.
The patients who took 100mg of the drug had global symptom improvement at eight and 12 weeks. Quality of life scores significantly improved, as well. Events, such as abdominal pain, constipation, nausea and vomiting, occurred most often with patients who received 200 mg doses.
More Articles on Gastroenterology:
Mailed Invitations May Increase Screenings for Noninvasive Tests
Study: Obese Black Americans Less Likely to Undergo Bariatric Surgery Than Whites
Increased Demand to Boost Endoscopy Global Market to $5.8B Value by 2018